The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
Zacks.com on MSN2d
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...
A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
The FTC also called for legislative reforms and "is encouraged to see bipartisan interest in Congress and among the states in addressing PBM practices," according to the report. Anjalee Khemlani is ...
A report from the Federal Trade Commission (FTC) has determined that pharmacy benefit managers (PBMs) are linked to significant cost increases for cancer, HIV, and other critical specialty drugs.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback